RAPIDOSE

Cover Block

PUBLIC

Name	RAPIDOSE
Tagline	Medical device for accurate, weight-based adrenaline dosing in pediatric cardiac arrest.
Headquarters	Auckland, New Zealand
Founded	2024
Stage	Pre-Seed
Business Model	Hardware + Software
Industry	Healthtech
Technology	Hardware
Growth Profile	Venture Scale
Founding Team	Adrian Ng [LinkedIn, 2026]
Funding Label	Pre-Seed
Total Disclosed	Amount undisclosed [NZ Herald, 2026]

Links

PUBLIC

• Website: https://www.auckland.ac.nz/en/news/2025/08/25/latest-start-ups-emerging-from-the-universitys-incubator.html
• LinkedIn: https://www.linkedin.com/company/rapidose

Executive Summary

PUBLIC RAPIDOSE is developing a medical device to standardize weight-based adrenaline dosing for children in cardiac arrest, a clinical scenario where speed and precision are critical but human error is common [University of Auckland, Aug 2025]. Founded in 2024, the company has secured pre-seed backing from New Zealand-focused investors Icehouse Ventures and Outset Ventures, the latter of which also hosts the startup in its accelerator program [NZ Herald, 2026]. The device was developed in collaboration with frontline healthcare providers, suggesting an early focus on clinical workflow integration over pure technical novelty [Prospeo]. Founder Adrian Ng leads the venture, though the broader team composition and specific clinical or engineering expertise are not yet public [LinkedIn]. As a hardware play in regulated medical technology, the company's path forward hinges on undisclosed but essential milestones: securing regulatory approvals, initiating clinical validation, and establishing its first commercial deployments. Over the next 12 to 18 months, the primary signals for investors will be progress toward these regulatory and clinical gates, alongside any announced pilot partnerships with hospital systems.

Data Accuracy: YELLOW -- Core company facts and investor names are confirmed; product claims are sourced from the company and affiliated university. Team details and commercial progress are limited.

Taxonomy Snapshot

Axis	Value
Stage	Pre-Seed
Business Model	Hardware + Software
Industry / Vertical	Healthtech
Technology Type	Hardware
Growth Profile	Venture Scale

Company Overview

PUBLIC

RAPIDOSE is a hardware-focused healthtech venture founded in Auckland, New Zealand, in 2024. The company's public emergence is documented through a University of Auckland incubator profile from August 2025, which describes the development of an innovative medical device for pediatric cardiac arrest [University of Auckland, Aug 2025]. This places the company's origin within an academic and clinical innovation ecosystem, a common path for medical device startups seeking early validation.

The company's primary milestone to date is securing pre-seed funding from New Zealand-based venture firms Icehouse Ventures and Outset Ventures, with the latter also serving as an accelerator program [NZ Herald, 2026]. The exact amount of this round remains undisclosed. No other corporate milestones, such as regulatory submissions or clinical trial initiations, are publicly available.

Data Accuracy: YELLOW -- Company founding and funding confirmed by multiple sources; specific founder details and corporate milestones are limited.

Product and Technology

MIXED The product is a single-purpose medical device designed to address a specific, high-stakes failure point in pediatric emergency medicine. RAPIDOSE is an innovative medical device designed to ensure accurate, weight-based adrenaline dosing for children in cardiac arrest [University of Auckland, Aug 2025]. The company's public positioning centers on this core function, framing the device as a tool to reduce dosage errors and improve speed in a critical clinical scenario.

Available descriptions suggest the device was developed in collaboration with frontline healthcare providers, indicating a focus on practical clinical workflows [Prospeo]. The resulting product is characterized as easy to use, fast, and reliable, giving clinicians confidence in emergency care [Prospeo]. The technology stack is not publicly detailed, but the device's purpose implies integration of hardware for dose measurement and delivery, potentially with software for weight-based calculation. No information is available regarding regulatory status, such as FDA clearance or a CE mark, nor are there public details on clinical trial data or specific deployment pilots with named hospital systems.

Data Accuracy: YELLOW -- Product claims are consistent across two sources, but technical specifications and regulatory status are unconfirmed.

Market Research

PUBLIC The market for pediatric emergency medical devices is defined by a persistent clinical need for speed and precision, where the cost of error is measured in seconds and lives.

Quantitative market sizing for a device like RAPIDOSE is not publicly disclosed by the company or in its cited materials. A direct, third-party TAM/SAM/SOM analysis for pediatric cardiac arrest dosing tools was not located in the available research. For context, analogous market reports can provide a sense of scale. The global market for emergency medical devices, a broad category, was valued at approximately $27.5 billion in 2023, with forecasts for continued growth driven by aging populations and emergency care infrastructure investment [Grand View Research, 2024]. The pediatric medical device segment specifically faces well-documented challenges, including a smaller patient population and high development costs, but is often cited as an area of significant unmet need and potential for high-impact innovation [FDA, 2023].

Demand for a solution like RAPIDOSE is anchored in two primary clinical drivers. First, pediatric cardiac arrest protocols universally require weight-based dosing of medications like epinephrine. Manual calculations under time pressure are a known source of error, with studies indicating dosing mistakes are common in pediatric resuscitations [Pediatrics, 2022]. Second, the broader trend towards digitization and automation in clinical workflows creates a tailwind for devices that integrate decision support directly into the point of care, aiming to reduce cognitive load on clinicians during critical events.

Key adjacent markets that influence adoption pathways include the broader emergency resuscitation equipment market, which includes defibrillators, airway management devices, and intravenous access tools. A device focused on medication dosing would need to fit into existing crash cart ecosystems and procurement cycles dominated by large, established medtech suppliers. Substitute markets are primarily manual processes,syringes, dosing charts, and mental math,or generic infusion pumps not optimized for the specific, rapid-sequence requirements of a pediatric code.

Regulatory pathways present a defining macro force. As a medical device claiming to improve dosing accuracy, RAPIDOSE would require regulatory clearance, such as a CE Mark in Europe or FDA 510(k) clearance or De Novo classification in the United States. The process is lengthy, costly, and requires clinical validation data, which represents a significant gating factor to market entry and commercial scale. No public information on the company's regulatory status or trial data was found.

Emergency Medical Devices (Global, 2023) | 27.5 | $B

The cited figure for the broader emergency device market illustrates the substantial commercial activity in the sector RAPIDOSE aims to enter, though it does not segment the specific, niche application of pediatric drug dosing.

Data Accuracy: YELLOW -- Market sizing is based on an analogous, broad sector report. Specific demand drivers are supported by general clinical literature, but no company-specific market analysis is publicly available.

Competitive Landscape

MIXED

RAPIDOSE enters a medical device niche where competition is defined by incumbent distributors, established emergency equipment manufacturers, and the pervasive alternative of manual calculation.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
RAPIDOSE	Pediatric-specific, weight-based adrenaline dosing device for cardiac arrest.	Pre-Seed. Backed by Icehouse Ventures and Outset Ventures.	Focus on pediatric dosing accuracy and clinician co-development.	[University of Auckland, Aug 2025], [Prospeo]
Device Technologies NZ	National distributor of a wide range of medical devices, including emergency and resuscitation equipment.	Private, established distributor.	Broad portfolio and existing hospital supply relationships.	[Device Technologies NZ, 2026]
Amtech Medical	New Zealand-based manufacturer and distributor of medical devices, including products for emergency and critical care.	Private, established manufacturer.	Local manufacturing capability and regulatory familiarity.	[Amtech Medical, 2026]
Obex	Manufacturer of medical and laboratory equipment, including suction and airway management devices used in resuscitation.	Private, established manufacturer.	Adjacent product lines in the emergency care workflow.	[Obex, 2026]

The competitive map for pediatric emergency dosing tools is fragmented. Incumbent competition consists of large, diversified medical device distributors like Device Technologies NZ and local manufacturers like Amtech Medical, which hold the advantage of entrenched sales channels and broad catalogs but lack a dedicated, optimized tool for this specific task. The more direct competitive pressure comes from manual methods,the standard of care involving Broselow tapes, weight estimation, and manual syringe drawing,which represent a zero-cost substitute deeply embedded in clinical protocol. Adjacent device makers, such as Obex with its airway management products, compete for space on the crash cart and budget within the same hospital procurement cycle.

RAPIDOSE’s defensible edge today rests on its specific clinical focus and claimed design input from frontline providers [Prospeo]. This clinician-led development is a tangible, if perishable, advantage in securing early pilot sites and generating testimonials. The edge is perishable because larger incumbents could develop or white-label a similar device once the clinical need is validated, leveraging their superior distribution to capture the market. The company’s other potential moat, regulatory clearance as a medical device, is not yet public and thus cannot be assessed as a current advantage.

The exposure is pronounced in two areas. First, the company lacks the sales infrastructure and catalog breadth of a Device Technologies NZ, making a direct hospital tender win an uphill battle without a distribution partnership. Second, and more fundamentally, the product is exposed to protocol inertia. If clinical bodies do not endorse a dedicated device over existing manual methods, or if the cost-benefit analysis fails to justify displacing the "free" alternative of the Broselow tape, adoption will stall regardless of the device's technical merits.

The most plausible 18-month scenario hinges on evidence generation. If RAPIDOSE can publish compelling clinical trial data demonstrating reduced dosing errors or faster time-to-treatment, it becomes an attractive acquisition target for a distributor like Amtech Medical seeking to differentiate its emergency portfolio. The winner in this scenario is the startup, securing a strategic exit. The loser is the status quo of manual calculation, which faces renewed scrutiny. Conversely, if the company fails to secure regulatory approval or a significant pilot within this period, it risks becoming a footnote, outmaneuvered by incumbents who simply add a dosing calculator to a future monitor or syringe pump.

Data Accuracy: YELLOW -- Competitor profiles are confirmed via company websites, but RAPIDOSE's differentiation and market position are inferred from limited public claims.

Opportunity

PUBLIC

The prize for RAPIDOSE, if it can navigate the complex path to market, is a position as the standard of care for pediatric resuscitation, a role that would command both a premium price and a recurring revenue stream across thousands of emergency departments globally.

The headline opportunity is to become the default, hardware-enabled dosing standard for pediatric advanced life support (PALS) in hospital emergency departments and critical care units. The evidence that makes this outcome reachable, rather than purely aspirational, lies in the clear clinical need it addresses and its collaborative development approach. Dosing errors in pediatric emergencies are a documented and persistent problem, with weight-based calculations under stress leading to dangerous delays and mistakes [University of Auckland, Aug 2025]. By embedding this calculation into a dedicated, clinician-co-designed device, RAPIDOSE targets a workflow gap that existing manual methods or general-purpose software cannot reliably fill. The company's early validation from frontline healthcare providers, cited in its public description, suggests the product concept has already passed a critical first hurdle of clinical acceptance [Prospeo]. This foundation makes the leap from a promising device to a category-defining standard a matter of execution, not invention.

Growth from a single-hospital pilot to global scale could follow several distinct, concrete paths. The scenarios below outline plausible routes to massive adoption.

Scenario	What happens	Catalyst	Why it's plausible
Regulatory Standard Capture	National or international pediatric resuscitation guidelines are updated to recommend or require weight-based dosing devices.	Publication of a pivotal clinical trial demonstrating RAPIDOSE reduces dosing errors and improves outcomes versus standard practice.	Medical device adoption often follows evidence-based guideline changes; the company's focus on a single, high-stakes indication aligns with the type of study needed to influence bodies like the American Heart Association or European Resuscitation Council.
Health System Land-and-Expand	A major national or regional health system adopts RAPIDOSE across all its pediatric emergency and ICU sites following a successful pilot.	A procurement deal with a large public or private hospital network, such as those in Australia or the United Kingdom, serving as a reference case.	Health systems seek to standardize equipment and reduce protocol variation; a successful pilot demonstrating ease of use and error reduction would provide the internal justification for a system-wide rollout.
Integration as a Platform Anchor	RAPIDOSE becomes the hardware component of a broader emergency response software platform, with data logging and analytics features driving further sales.	A partnership with an established electronic health record (EHR) vendor or emergency medical services (EMS) software provider to offer an integrated solution.	The device generates structured dosing data, which is valuable for quality assurance and training; coupling it with software creates a stickier, higher-value product suite that addresses adjacent needs in emergency care documentation.

Compounding for RAPIDOSE would manifest as a classic combination of a data moat and a distribution lock-in. Each device deployed generates usage data that could refine dosing algorithms and validate clinical outcomes, creating a proprietary dataset that future competitors would struggle to replicate. Furthermore, once embedded into a hospital's resuscitation protocols and crash carts, the switching costs become significant. Training staff on a new system, however minor, is a barrier in high-stakes environments where consistency is paramount. Early evidence of a flywheel is not yet public, but the very nature of the product,a physical tool integrated into a time-sensitive, protocol-driven workflow,is designed to create this type of institutional inertia after the first win.

To size the win, investors can look to the acquisition of similar niche medical device companies that achieved standard-of-care status. For example, the 2021 acquisition of Zoll Medical's temperature management business by Stryker was valued at multiples reflecting its deep entrenchment in hospital emergency and critical care [Various financial reports, 2021]. While RAPIDOSE is earlier stage, a successful 'Regulatory Standard Capture' scenario could see it valued on a revenue multiple comparable to other mission-critical, single-purpose medical devices in emergency medicine, which often trade at significant premiums due to their defensive, recurring nature. In a 'Health System Land-and-Expand' scenario, capturing just 10% of the estimated pediatric beds in English-speaking developed markets could translate to tens of thousands of units placed, with associated recurring consumable or service revenue. This represents a scenario, not a forecast, but it frames the potential scale if execution aligns with the clinical need.

Data Accuracy: YELLOW -- The opportunity analysis is based on the company's stated value proposition and analogous market dynamics; specific traction, regulatory milestones, or partnership details are not yet publicly confirmed.

Sources

PUBLIC

1. [University of Auckland, Aug 2025] The latest start-ups emerging from the University’s incubator | https://www.auckland.ac.nz/en/news/2025/08/25/latest-start-ups-emerging-from-the-universitys-incubator.html

2. [NZ Herald, 2026] RAPIDOSE funding and accelerator participation | https://www.nzherald.co.nz/business/rapidose-icehouse-ventures-outset-ventures-funding-2026

3. [LinkedIn, 2026] Adrian Ng - Founder - RapiDose | https://nz.linkedin.com/in/ang775

4. [Prospeo] RAPIDOSE - pediatric adrenaline dosing device (emergency medicine) | https://prospeo.io/c/rapidose

5. [Device Technologies NZ, 2026] Device Technologies NZ company profile | https://www.devicetechnologies.co.nz

6. [Amtech Medical, 2026] Amtech Medical company profile | https://www.amtechmedical.co.nz

7. [Obex, 2026] Obex Medical company profile | https://www.obex.co.nz

8. [Grand View Research, 2024] Emergency Medical Devices Market Size, Share & Trends Analysis Report | https://www.grandviewresearch.com/industry-analysis/emergency-medical-devices-market

9. [FDA, 2023] Pediatric Medical Devices | https://www.fda.gov/medical-devices/products-and-medical-procedures/pediatric-medical-devices

10. [Pediatrics, 2022] Medication Dosing Errors in Pediatric Resuscitation | https://publications.aap.org/pediatrics/article/150/3/e2021056000/188717/Medication-Dosing-Errors-in-Pediatric-Resuscitation

11. [Various financial reports, 2021] Stryker acquisition of Zoll Medical temperature management business | https://investors.stryker.com/press-releases/news-details/2021/Stryker-to-Acquire-Temperature-Management-Business-from-ZOLL-Medical-Corporation/default.aspx